New blood test developed to track Alzheimer’s disease progression
Researchers presenting at the Clinical Trials on Alzheimer’s Disease conference in Boston have unveiled a new blood test capable of identifying the stage of Alzheimer's disease progression within the brain. Developed by Alamar Biosciences, the test measures the levels of a specific biomarker known as eMTBR-tau.
This biomarker reflects the accumulation of tau protein tangles in brain cells, offering a more detailed view of the disease's advancement compared to traditional tests. While existing diagnostic tools primarily focus on amyloid-beta and phosphorylated tau proteins—which serve as early indicators—they often lack precision regarding the later stages of tau accumulation. This new method aims to address that gap by providing deeper insights into the pathology as it evolves.
Currently, there are two approved Alzheimer's medications on the market that target amyloid-beta plaques, while multiple other drug candidates currently in development are specifically focused on the tau protein. Experts suggest that the ability to track these tangles could significantly enhance clinical trials and patient monitoring, as managing tau accumulation remains a major hurdle in effective diagnosis and treatment of the disease.